Skip to main content
Equibles

Paul Matteis

Analyst

Stifel

Equibles does not estimate personal net worth.

About Paul Matteis

Paul Matteis is recorded as Analyst at Stifel. Paul Matteis has spoken on 6 earnings calls across 5 companies, most recently for COMPASS Pathways plc on May 13, 2026. Those appearances were for Vertex Pharmaceuticals Inc (VRTX), COMPASS Pathways plc (CMPS), Neurocrine Biosciences Inc (NBIX), Biomarin Pharmaceutical Inc (BMRN) and Alnylam Pharmaceuticals, Inc. (ALNY). The companies whose calls Paul Matteis spoke on are classified in the Healthcare sector.

Paul Matteis on recent calls

“I appreciate you taking our questions, and congrats on all the great progress. Just two from us.”
Analyst — Stifel, COMPASS Pathways plc Q1 FY2026 Earnings Call ·
“I'm not sure how limited you are and how you can speak about Amicus and things going forward, but I thought I'd give it a brief try.”
Analyst — Stifel, Biomarin Pharmaceutical Inc Q4 FY2025 Earnings Call ·
“I was wondering, Jeff, if you could try to help do some math for us on the call as it relates to the headwind this quarter from selling weeks. I know you talked about two selling weeks, but I think that might be related to one specific SP.”
Analyst — Stifel, Alnylam Pharmaceuticals, Inc. Q1 FY2025 Earnings Call ·
“One AAT and one commercial, if you don't mind. On AAT, in the 814 press release, you mentioned that analysis of the PK data from the study indicated the exposure levels were low.”
Analyst — Stifel, Vertex Pharmaceuticals Inc / Ma Q3 FY2020 Earnings Call ·

Affiliation history

  • Stifel

    Analyst

    Source not stated

    Current

Company network

Recent activity